MET drugs for Non-Small Cell Lung Cancer

13 tracked MET drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the MET page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.

3 approved / phase 45 Phase 31 Phase 22 Phase 1/21 Phase 11 preclinical / unstaged

Head-to-head evidence: ASKC202 vs Capmatinib · ASKC202 vs Savolitinib · ASKC202 vs Tepotinib · ASKC202 vs Vebreltinib · Capmatinib vs CKD-703 · CKD-703 vs Savolitinib

The roster

← all MET drugs